Torrent Pharmaceuticals Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 3464, up 2.43% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.98% on the day, quoting at 23962.25. The Sensex is at 79274.83, down 1.13%. Torrent Pharmaceuticals Ltd has risen around 11.67% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has risen around 3.99% in last one month and is currently quoting at 22314.55, up 1.32% on the day. The volume in the stock stood at 3.15 lakh shares today, compared to the daily average of 3.56 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 3468.45, up 2.22% on the day. Torrent Pharmaceuticals Ltd is up 61.34% in last one year as compared to a 13.3% spurt in NIFTY and a 40.24% spurt in the Nifty Pharma index.The PE of the stock is 69.93 based on TTM earnings ending September 24.Powered by Capital Market - Live

The brands include Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin), which are used in the treatment of type 2 diabetes. Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor which is indicated for glycemic control in adults with type 2 diabetes mellitus. The market for SGLT-2 inhibitors is valued at Rs 3,235 crore and the SGLT-2 inhibitors are growing faster than the diabetes market at 25% CAGR. As per the International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2024 data, the Indian diabetes medications market is valued at Rs 19,912 crore, growing at 7.7% CAGR over the last 4 years. The acquisition is expected to be completed in March 2025. The company has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology. The company's consolidated net profit increased 17.35% to Rs 453 crore on 8.6% rise in revenue from operations to Rs 2,889 crore in Q2 FY25 over Q2 FY24. The scrip shed 0.31% to Rs 3,339.25 on the BSE. Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 3387.2, up 1.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Torrent Pharmaceuticals Ltd has added around 5.83% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 2.69 lakh shares today, compared to the daily average of 3.54 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 3392.4, up 1.23% on the day. Torrent Pharmaceuticals Ltd is up 58.76% in last one year as compared to a 18.09% gain in NIFTY and a 38.64% gain in the Nifty Pharma index.The PE of the stock is 69.06 based on TTM earnings ending September 24.Powered by Capital Market - Live

'Based on the company assessment, the company will pursue an appeal and is hopeful of favorable outcome at higher forum and does not expect the said Order to have any material financial impact on the company,' it added. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology. The company's consolidated net profit increased 17.35% to Rs 453 crore on 8.6% rise in revenue from operations to Rs 2,889 crore in Q2 FY25 over Q2 FY24. Shares of Torrent Pharmaceuticals rallied 3.11% to currently trade at Rs 3,303.40 on the BSE.Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 3217.6, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.57% on the day, quoting at 24282.7. The Sensex is at 80152.78, up 1.31%. Torrent Pharmaceuticals Ltd has dropped around 2.99% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has dropped around 2.85% in last one month and is currently quoting at 21962.05, up 1.11% on the day. The volume in the stock stood at 1.64 lakh shares today, compared to the daily average of 5.43 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 3211.45, up 1.13% on the day. Torrent Pharmaceuticals Ltd is up 54.77% in last one year as compared to a 22.09% gain in NIFTY and a 39.66% gain in the Nifty Pharma index.The PE of the stock is 65.59 based on TTM earnings ending September 24.Powered by Capital Market - Live

The United States Food and Drug Administration (USFDA) conducted inspection at Pithampur manufacturing facility from 16 September to 20 September 2024. At the end of the inspection, the agency issued a Form FDA 483 with one observation. The US drug regulator has now successfully closed by the inspection by issuing EIR with VAI to the said facility. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology. The company's consolidated net profit increased 17.35% to Rs 453 crore on 8.6% rise in revenue from operations to Rs 2,889 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

Capri Global Capital Ltd, Marico Ltd, Honeywell Automation India Ltd, Laxmi Organic Industries Ltd are among the other stocks to see a surge in volumes on BSE today, 30 October 2024.Torrent Pharmaceuticals Ltd registered volume of 106.33 lakh shares by 10:47 IST on BSE, a 2179.99 fold spurt over two-week average daily volume of 4878 shares. The stock slipped 2.38% to Rs.3,134.50. Volumes stood at 7419 shares in the last session.Capri Global Capital Ltd clocked volume of 3.17 lakh shares by 10:47 IST on BSE, a 34.85 times surge over two-week average daily volume of 9093 shares. The stock gained 13.53% to Rs.209.80. Volumes stood at 5128 shares in the last session.Marico Ltd recorded volume of 1.91 lakh shares by 10:47 IST on BSE, a 9.7 times surge over two-week average daily volume of 19653 shares. The stock gained 3.87% to Rs.653.15. Volumes stood at 26022 shares in the last session.Honeywell Automation India Ltd witnessed volume of 744 shares by 10:47 IST on BSE, a 4.3 times surge over two-week average daily volume of 173 shares. The stock dropped 7.54% to Rs.45,297.20. Volumes stood at 128 shares in the last session.Laxmi Organic Industries Ltd saw volume of 2.9 lakh shares by 10:47 IST on BSE, a 4.05 fold spurt over two-week average daily volume of 71540 shares. The stock increased 8.61% to Rs.274.35. Volumes stood at 83736 shares in the last session.Powered by Capital Market - Live

Revenue from operations rose 8.60% year on year (YoY) to Rs 2,889 crore in the quarter ended 30 September 2024. Profit before tax stood at Rs 661 crore in September 2024 quarter, up 18.24% from Rs 559 crore posted in same quarter last year. Operating EBITDA stood at Rs 939 crore in Q2 FY25, registering a growth of 13.81% as against Rs 825 crore reported in Q2 FY24. The company's India revenue grew by 13% YoY to Rs 1,632 crore in Q2 FY25, led by outperformance in focus therapies. As per All India Organization of Chemists & Druggists (AIOCD) secondary market data, IPM growth for the quarter was 8%. Torrent's chronic business grew at 14% versus IPM growth of 9%, driven by strong revival in cardiac divisions and continued traction in anti-diabetes (OAD) new launches. Torrent Pharma's Brazil revenue rose by 4% to Rs 263 crore and on constant currency terms revenues was up by 17% at R$ 174 million. As per IQVIA, market growth for the quarter was 8%. Growth was aided by performance of top brands, new launches and growth in generic segment. The Germany revenue stood at Rs 288 crore, by 8%. Constant currency revenue at Euro 31 million was up by 6%. Growth momentum continues with incremental tender wins since last five quarters. The company's US revenue stood at Rs 268 crore in Q2 FY25, up by 8%. Constant currency revenue was at $32 million, up by 7% YoY. Sequential quarter sales were at a similar level. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology. Shares of Torrent Pharmaceuticals rallied 3.63% to end at Rs 3,436.65 on the BSE.Powered by Capital Market - Live

Net profit of Torrent Pharmaceuticals rose 17.36% to Rs 453.00 crore in the quarter ended September 2024 as against Rs 386.00 crore during the previous quarter ended September 2023. Sales rose 7.72% to Rs 2831.00 crore in the quarter ended September 2024 as against Rs 2628.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2831.002628.00 8 OPM %33.1731.39 - PBDT859.00760.00 13 PBT661.00559.00 18 NP453.00386.00 17 Powered by Capital Market - Live

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live